Mohammed Imran Hamzah

Mohammed Imran Hamzah

Auto-generated profile, based on publicly available information

Mohammed Imran Hamzah

College of Medicine, Al-Nahrain University, Baghdad, Iraq

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2020 in VirusDisease
Verified
Journal Article
Closed access
PDF file
AAAhmed Ghdhban Al-Ziaydi
Ahmed Ghdhban Al-Ziaydi
Ahmed Majeed Al-ShammariAhmed Majeed Al-Shammari
Ahmed Majeed Al-Shammari
MHMohammed I. Hamzah
Mohammed I. Hamzah
HKHaider Sabah Kadhim
Haider Sabah Kadhim
MJMajid Sakhi Jabir
Majid Sakhi Jabir

1 April 2024 in AL-Kindy College Medical Journal
Verified
Journal Article
Open access
PDF file
SHSaif Ali Abdul Haleem
Saif Ali Abdul Haleem
MHMohammed I. Hamzah
Mohammed I. Hamzah
MKMahmood Shakir Khudhair
Mahmood Shakir Khudhair
EDEsraa Qais Deli
Esraa Qais Deli
Background: Meteorin-like, is an innovative adipokine, that exhibits elevated expression within adipose tissue and confers advantageous effects upon energy metabolism. Nevertheless, current research pertaining to circulating Meteorin-like levels in obesity remains limited and incongruent. Thus, the objective of this study was to assess Metrnl serum concentrations among adult individuals with pre-diabetes and newly diagnosed type 2 diabetes mellitus and examine its correlation with glucose, HbA1C, and lipid metabolism. Subjects and Methods: The case-control study incorporated 120 subjects, who were then segregated into three distinct groups, namely control (n = 60), pre-diabetes (n = 30), and newly diagnosed type 2 diabetes mellitus patient’s (n = 30). The quantification of serum Meteorin-like concentrations was undertaken by employing an enzyme-linked immunosorbent assay. Results: The data of the current study demonstrates a significant increase in the concentration of Meteorin-like protein in individuals with newly diagnosed type 2 diabetes mellitus patients as compared to those without the condition (p ≤ 0.001). A positive correlation between METRNL and various metabolic parameters, such as BMI, FBS, HbA1C, TC, TG, and LDL-C, was observed using the Pearson correlation coefficient. Conversely, a negative correlation was observed between METRNL and HDL-C as well as VLDL-C. Conclusions: The present study has revealed that serum Meteorin-like levels were found to be elevated in both individuals having newly diagnosed type 2 diabetes mellitus patients and pre-diabetes. Furthermore, the association between serum Meteorin-like levels and lipid profile was observed to be dependent. These findings strongly suggest that the modification of circulating Meteorin-like levels may serve as a promising biomarker for the prognosis of type 2 diabetes mellitus.

31 March 2019 in Journal of Pure and Applied Microbiology
Verified
Journal Article
Open access
BABatool Hassan Al-Ghurabi
Batool Hassan Al-Ghurabi
AYAbeer Khalid Yaseen
Abeer Khalid Yaseen
MHMohammed Imran Hamzah
Mohammed Imran Hamzah

1 January 2020
Verified
Journal Article
Closed access
BDBasheer Sultan Dayir
Basheer Sultan Dayir
MHMohammedI Hamzah
MohammedI Hamzah
MKMahmood S.H. Khudair
Mahmood S.H. Khudair

5 May 2026 in Journal of Associated Medical Sciences
Verified
Journal Article
Open access
SASajjad Ashour
Sajjad Ashour
MHMohammed Hamzah
Mohammed Hamzah
MKMahmood Shakir Khudhair
Mahmood Shakir Khudhair
Background: Meteorin-like protein (Metrnl) is an adipokine mostly produced and secreted by adipose tissue. Metrnl is an adipokine that enhances insulin sensitivity, promotes the browning of adipose tissue, and increases energy expenditure. Objectives: This study aimed to investigate alterations in serum Metrnl levels in patients with Graves’ disease (GD) and subclinical hyperthyroidism (SCH), with the objective of assessing its potential as a diagnostic biomarker. Materials and methods: This case-control study was matched for age, sex, and BMI and included 40 patients with GD, 40 with SCH, and 80 controls. The average ages of the participants ranged from 22 to 59 years. Samples were obtained from July 2025 to January 2026. Metrnl levels were measured using a sandwich enzyme-linked immunosorbent assay. T4 and TSH levels were evaluated using the VIDAS system (bioMérieux), whereas thyroid-stimulating hormone receptor antibodies (TRAb) were detected using the Roche Cobas e411 Analyzer. The Roche Cobas c111 Analyzer was employed to evaluate lipid profiles. Results: The mean serum Metrnl levels in the control group were 11.7±1.9 ng/mL. In contrast, patients with GD had a significantly elevated mean Metrnl level of 22.1±2.3 ng/mL (p<0.001). The SCH group had a markedly elevated mean concentration of 22.4±2.8 ng/mL (p<0.001) compared to the control group. Serum concentrations of TSH, total cholesterol, triglycerides, LDL, and VLDL were markedly reduced in both GD and SCH relative to controls (p<0.001). T4 and TRAb levels were significantly elevated in GD and SCH compared with controls (p<0.001). Conclusion: Elevated levels of Metrnl in Graves’ disease suggest its potential as a new biomarker for diagnosis and evaluation of metabolic risks, alongside conventional thyroid function tests.

1 January 2019 in Indian Journal of Public Health Research & Development
Verified
Journal Article
Closed access
MHMohammed I. Hamzah
Mohammed I. Hamzah
IKIsraa A. Abdul Kareem
Israa A. Abdul Kareem
MAMohammed Albayati
Mohammed Albayati